New Berlin, WI, United States of America

Magdalena Alonso-Galicia


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2002-2003

Loading Chart...
3 patents (USPTO):Explore Patents

Title: **The Innovative Journey of Magdalena Alonso-Galicia: A Pioneer in 20-HETE Therapeutics**

Introduction

Magdalena Alonso-Galicia is an esteemed inventor based in New Berlin, Wisconsin. With a remarkable portfolio of three patents, she has made significant contributions to the field of therapeutic applications related to 20-HETE agonists and antagonists. Her groundbreaking work continues to influence advancements in biomedical research.

Latest Patents

One of her latest patents involves the disclosure of 20-HETE agonists and antagonists, which aims to highlight their therapeutic applications. The preferred forms of her inventions include specific agonists such as 21-hydroxyheneicosa-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid and 20-hydroxyeicosa-5(Z), 14(Z)-dienoic acid. Additionally, her research identifies key antagonists, including 5(S)-HETE, 15(S)-HETE, and 19(S)-HETE, among others. This innovative work strives to enhance treatment methods for various health conditions.

Career Highlights

Magdalena is an integral part of the Medical College of Wisconsin Research Foundation, Inc., where her research plays a vital role in the development of new therapeutic solutions. Her contributions to the scientific community have established her as a prominent figure in the field of medical innovations.

Collaborations

Throughout her career, Magdalena has collaborated with distinguished colleagues, including Richard J. Roman and John Russell Falck. These partnerships have facilitated groundbreaking research and advancements in her field, showcasing the power of teamwork in driving innovation.

Conclusion

Magdalena Alonso-Galicia's journey as an inventor serves as an inspiration to many in the realm of biomedical research. With her extensive patents and collaborations, she continues to pave the way for innovative therapeutic applications, particularly in the area of 20-HETE. Her dedication to research exemplifies the spirit of innovation that drives progress in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…